Dr. Baram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
834 Walnut Street Suite 650
Philadelphia, PA 19107Phone+1 215-955-6591Fax+1 215-955-0830
Education & Training
- Brown UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
- Christiana Care Health ServicesResidency, Internal Medicine/Emergency Medicine, 1997 - 2002
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997
Certifications & Licensure
- PA State Medical License 2006 - 2024
- DE State Medical License 1999 - 2009
- RI State Medical License 2003 - 2006
- MA State Medical License 2003 - 2004
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Convalescent Plasma for the Treatment of COVID-19 Start of enrollment: 2020 Apr 15
- Trial of Therapeutic Hypothermia in Patients With ARDS Start of enrollment: 2021 Jun 29
Roles: Contact, Principal Investigator
- Novel Experimental COVID-19 Therapies Affecting Host Response Start of enrollment: 2021 Jul 15
Roles: Contact
Publications & Presentations
PubMed
- 16 citationsUtilidad de la broncoscopia flexible en la evaluación de infiltrados pulmonares en la población con trasplante de células madre hemopoyéticas: experiencia de 14años en...Christopher R. Gilbert, Andrew D. Lerner, Michael Baram, Bharat Awsare
Archivos De Bronconeumologia. 2013-05-01 - 12 citationsPoor Positive Predictive Value of McConnell's Sign on Transthoracic Echocardiography for the Diagnosis of Acute Pulmonary EmbolismUrvashi Vaid, Esmé F Singer, Gregary D. Marhefka, Walter K. Kraft, Michael Baram
Hospital Practice. 2013-08-01 - 2 citationsOutcomes of extracorporeal membrane oxygenation in immunosuppressed vs. Immunocompetent patients.Cameron Blazoski, Pradhab Kirupaharan, Robert Hilton, Ron Leong, Michael Baram
Heart & Lung. 2022-12-17
Press Mentions
- COVID-19 Trials Opening at Accelerated RateMay 5th, 2020
- Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 InfectionApril 9th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: